Education
About Us
Working with TipRanks
Follow Us
arGEN X (GB:0QW0)
:0QW0
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
2.59Last Year’s EPS
0.42Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: -8.34%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Positive
The earnings call reflected strong revenue growth and successful market expansion, particularly with the launch of the VYVGART pre-filled syringe. Positive clinical data and financial strength were highlighted, alongside significant progress in the pipeline. However, the call acknowledged the impact of Medicare Part D reform and typical Q1 seasonality as challenges. Overall, the positive aspects outweigh the lowlights, showcasing the company's robust performance and strategic positioning.Company Guidance
During the call, Argenx provided guidance highlighting its strategic objectives and financial performance for the first quarter of fiscal year 2025. The company aims to reach 50,000 patients across 10 labeled indications and advance five Phase III assets by Vision 2030. In Q1 2025, Argenx reported total operating income of $807 million, with product net sales of $790 million, marking a 99% growth compared to the prior year. The sales were distributed as $681 million in the U.S., $32 million in Japan, $57 million in the rest of the world, and $20 million from product supply to Zai Lab in China. The company experienced a 7% quarter-over-quarter growth, despite typical Q1 seasonality and impacts from Medicare redesign. Argenx launched VYVGART Hytrulo pre-filled syringe for self-injection in the U.S. and Germany, aiming to expand patient reach in gMG and CIDP. The gross margin remained strong at 90%, with a 16% effective tax rate, resulting in a quarterly profit of $169 million. Argenx maintains a robust cash position, with $3.6 billion in cash, cash equivalents, and current financial assets. The company is confident in its strategy to drive consistent growth and innovation, leveraging its strong financial position to deliver long-term value.Strong Revenue Growth
Total operating income for Q1 2025 was $807 million, reflecting a 99% growth in product net sales compared to the prior year quarter. The U.S. contributed $681 million, Japan $32 million, and the rest of the world $57 million.
VYVGART Expansion Success
The company successfully launched the pre-filled syringe for VYVGART in the U.S. and Germany, contributing to patient growth in gMG and CIDP markets. VYVGART achieved the fastest market share growth among branded biologics in gMG.
Positive Clinical Data
New data from the ADVANCE-NEXT study showed 56.5% of gMG patients achieved minimum symptom expression during treatment. VYVGART continues to demonstrate sustained efficacy and improved quality of life measures.
Financial Strength
The company reported a gross margin of 90% and an operating profit of $139 million for Q1 2025. The cash balance at quarter-end was $3.6 billion, an increase of $238 million from Q4 2024.
Pipeline Progress
Argenx is advancing 10 registrational and 10 proof-of-concept studies, including Phase III assets and INDs for ARGX-109 and ARGX-213. The company plans several readouts across its pipeline for the year.
GB:0QW0 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GB:0QW0 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | €549.35 | €488.35 | -11.10% |
Feb 27, 2025 | €598.91 | €609.95 | +1.84% |
Oct 31, 2024 | €513.16 | €529.63 | +3.21% |
Jul 25, 2024 | €435.19 | €450.99 | +3.63% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does arGEN X (GB:0QW0) report earnings?
arGEN X (GB:0QW0) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is arGEN X (GB:0QW0) earnings time?
arGEN X (GB:0QW0) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of arGEN X stock?
The P/E ratio of arGEN X is N/A.
What is GB:0QW0 EPS forecast?
GB:0QW0 EPS forecast for the fiscal quarter 2025 (Q2) is 2.59.